Jack H. Landmann
Research Subjects
Jack H. Landmann has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Mehmet Emrah Selli
Division of Oncology, Section of Cellular Therapies, Washington University School of Medicine, St Louis, USA
31 shared publications - Nathan Singh
Washington University School of Medicine
31 shared publications - Ju-Fang Chang
Center for Gene and Cellular Immunotherapy, Washington University School of Medicine, St. Louis, Missouri. 2
30 shared publications - Alex S. Holehouse
Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, USA
18 shared publications - Deepesh Kumar Gupta
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
18 shared publications - John F. DiPersio
Department of Medicine, Washington University in St. Louis, St. Louis, USA
18 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 7 | a, Overlay of predicted mut031 α chain variable region and resolved FMC63 variable chain structure. Modeling performed using AlphaFold2. b, Memory lineages of human T cells engineered to express miTCR1 WT or mut035 at the conclusion of manufacturing cultures. c-d, Proportion of human T cells that were early lineage (naïve or central memory) c, throughout 6 day stimulation manufacturing cultures or d, one day after clearance of Nalm6. e, Expansion of human T cells expressing miTCR1 WT, mut035 or 19/BBζ CAR from two donors. b-d, data from one donor.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 7 | a, Overlay of predicted mut031 α chain variable region and resolved FMC63 variable chain structure. Modeling performed using AlphaFold2. b, Memory lineages of human T cells engineered to express miTCR1 WT or mut035 at the conclusion of manufacturing cultures. c-d, Proportion of human T cells that were early lineage (naïve or central memory) c, throughout 6 day stimulation manufacturing cultures or d, one day after clearance of Nalm6. e, Expansion of human T cells expressing miTCR1 WT, mut035 or 19/BBζ CAR from two donors. b-d, data from one donor.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 2 | a-d, Expression of a, TCR constant chains and mCherry transduction marker, b, FMC63 and mCherry transduction marker, c, FMC63 and TCR constant chains and d, CD3ε and TCR constant chains in primary human T cells engineered with CARs or miTCRs. e, Comparison of surface FMC63 expression in miTCR1 and miTCR2 engineered T cells in n=6 independent donors. f, Median fluorescence intensity (MFI) of APC on T cells that bound soluble CD19-APC conjugate. a-d, Representative of five independent donors. Analysis using Student’s t-test or two-way ANOVA.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 2 | a-d, Expression of a, TCR constant chains and mCherry transduction marker, b, FMC63 and mCherry transduction marker, c, FMC63 and TCR constant chains and d, CD3ε and TCR constant chains in primary human T cells engineered with CARs or miTCRs. e, Comparison of surface FMC63 expression in miTCR1 and miTCR2 engineered T cells in n=6 independent donors. f, Median fluorescence intensity (MFI) of APC on T cells that bound soluble CD19-APC conjugate. a-d, Representative of five independent donors. Analysis using Student’s t-test or two-way ANOVA.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 5 | a-b, Expression of TCR constant chains on the surface of a, Jurkat and b, human T cells transduced with miTCR variants. c-d, Comparison of surface TCR expression in miTCR1 and miTCR2 variant engineered c, Jurkats and d, human T cells. e, Change in surface expression of TCR constant chains based on presence or absence of PD insertion in the miTCRα chain. f, Expression of NFAT and g, NFκB in reporter Jurkat cells expressing 1G4 or miTCR variants in response to Nalm6. h, Expansion of human T cells expressing miTCR1 and miTCR2 variants upon exposure to Nalm6. d, cumulative data from three independent donors. b,e, representative data from three independent donors. Screening studies in h performed using two independent donors. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by Student’s t-test (c-e).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 5 | a-b, Expression of TCR constant chains on the surface of a, Jurkat and b, human T cells transduced with miTCR variants. c-d, Comparison of surface TCR expression in miTCR1 and miTCR2 variant engineered c, Jurkats and d, human T cells. e, Change in surface expression of TCR constant chains based on presence or absence of PD insertion in the miTCRα chain. f, Expression of NFAT and g, NFκB in reporter Jurkat cells expressing 1G4 or miTCR variants in response to Nalm6. h, Expansion of human T cells expressing miTCR1 and miTCR2 variants upon exposure to Nalm6. d, cumulative data from three independent donors. b,e, representative data from three independent donors. Screening studies in h performed using two independent donors. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by Student’s t-test (c-e).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 3 | a, Predicted structures of miTCR1 and miTCR2 α and β chains overlaid on resolved structures of TCR α and β chains. b, Overlay of five highest-ranking predictions for miTCR1 and miTCR2 variable-constant chain interface. c, Resolved native TCR α chain V-C interface structure and predicted V-C interface structures of miTCR2 WT and modified α chains. d, Resolved native TCR β chain V-C interface structure and predicted V-C interface structures of miTCR1 WT, miTCR2 WT and modified β chains.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 3 | a, Predicted structures of miTCR1 and miTCR2 α and β chains overlaid on resolved structures of TCR α and β chains. b, Overlay of five highest-ranking predictions for miTCR1 and miTCR2 variable-constant chain interface. c, Resolved native TCR α chain V-C interface structure and predicted V-C interface structures of miTCR2 WT and modified α chains. d, Resolved native TCR β chain V-C interface structure and predicted V-C interface structures of miTCR1 WT, miTCR2 WT and modified β chains.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 6 | a-b, Cytotoxicity of a, miTCR1 and b, miTCR2 variants against Nalm6. c-d, Long-term flow cytometry-based cytotoxicity of lead c, miTCR1 and d, miTCR2 variants. e, Quantification of cytokines in supernatants 24h after co-culture of engineered T cells with Nalm6. f, Expression of TCRC chains in αCD22 miTCR1, CD22 miTCR2 and CD19 miTCR1 engineered Jurkat cells. g, Induction of reporter NFAT-GFP upon exposure to CD19+CD22+ Nalm6 in Jurkat cells. Screening studies in a-b performed using two independent donors; c-d, representative data from three independent donors; e, data from one donor. ****P < 0.0001 by two-way ANOVA (c-d).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 6 | a-b, Cytotoxicity of a, miTCR1 and b, miTCR2 variants against Nalm6. c-d, Long-term flow cytometry-based cytotoxicity of lead c, miTCR1 and d, miTCR2 variants. e, Quantification of cytokines in supernatants 24h after co-culture of engineered T cells with Nalm6. f, Expression of TCRC chains in αCD22 miTCR1, CD22 miTCR2 and CD19 miTCR1 engineered Jurkat cells. g, Induction of reporter NFAT-GFP upon exposure to CD19+CD22+ Nalm6 in Jurkat cells. Screening studies in a-b performed using two independent donors; c-d, representative data from three independent donors; e, data from one donor. ****P < 0.0001 by two-way ANOVA (c-d).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 4 | Names and amino acid changes of miTCR variant panel. PD insertions are highlighted in blue.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 4 | Names and amino acid changes of miTCR variant panel. PD insertions are highlighted in blue.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors
A, Expansion of T cells in which stimulation cultures did or did not contain IL7/IL15. B, CD4 and CD8 composition of and C, memory composition of T cell products at the conclusion of manufacturing when stimulation cultures did or did not include IL7/IL15.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors
A, Expansion of T cells in which stimulation cultures did or did not contain IL7/IL15. B, CD4 and CD8 composition of and C, memory composition of T cell products at the conclusion of manufacturing when stimulation cultures did or did not include IL7/IL15.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors
A, Representative ow cytometry plots of transduction efficiency of various synthetic receptors in control (unedited) and TRAC+TRBCKO T cells when editing is performed pre-stimulation. B, Stability of CRISPR editing over-time when performing post-stimulation editing.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors
A, Representative ow cytometry plots of transduction efficiency of various synthetic receptors in control (unedited) and TRAC+TRBCKO T cells when editing is performed pre-stimulation. B, Stability of CRISPR editing over-time when performing post-stimulation editing.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 1 | a-b, Expression of NFAT and NFκB in reporter Jurkat cells expressing CARs or miTCRs in response to a, CD19+ Nalm6 or CD19- Molm14. b, Representative flow cytometry plot of TCR constant chain expression after dual TRAC and TRBC disruption. c, Summary data of TCR surface expression after dual TRAC and TRBC disruption in n=8 individual donors. Analysis using two-sided Student’s t-test.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Supplementary Figure 1 | a-b, Expression of NFAT and NFκB in reporter Jurkat cells expressing CARs or miTCRs in response to a, CD19+ Nalm6 or CD19- Molm14. b, Representative flow cytometry plot of TCR constant chain expression after dual TRAC and TRBC disruption. c, Summary data of TCR surface expression after dual TRAC and TRBC disruption in n=8 individual donors. Analysis using two-sided Student’s t-test.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors
Supplementary Tables S1 and S2
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors
Supplementary Tables S1 and S2